Patents by Inventor John Edward Park

John Edward Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT RHABDOVIRUS ENCODING FOR CCL21
    Publication number: 20240000874
    Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.
    Type: Application
    Filed: June 5, 2023
    Publication date: January 4, 2024
    Inventors: Philipp MUELLER, Klaus ERB, Patrik ERLMANN, Tobias Friederike NOLDEN, John Edward PARK, Guido WOLLMANN
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20230372297
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as herein, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: August 2, 2023
    Publication date: November 23, 2023
    Inventors: John Edward PARK, Gerald Juergen ROTH, Armin HECKEL, Nveed CHAUDHARY, Trixi BRANDL, Georg DAHMANN, Matthias GRAUERT
  • Recombinant rhabdovirus encoding for CCL21
    Patent number: 11707495
    Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: July 25, 2023
    Assignees: Boehringer Ingelheim International GmbH, ViraTherapeutics GmbH
    Inventors: Philipp Mueller, Klaus Erb, Patrik Erlmann, Tobias Friederike Nolden, John Edward Park, Guido Wollmann
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20200330435
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: July 6, 2020
    Publication date: October 22, 2020
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • RECOMBINANT RHABDOVIRUS ENCODING FOR CCL21
    Publication number: 20200237838
    Abstract: The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a CCL21 protein. The invention is further directed to the use of the recombinant virus in the treatment of cancer, and also to methods for producing such viruses.
    Type: Application
    Filed: January 24, 2020
    Publication date: July 30, 2020
    Inventors: Philipp MUELLER, Klaus ERB, Patrik ERLMANN, Tobias Friederike NOLDEN, John Edward PARK, Guido WOLLMANN
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DEISEASES
    Publication number: 20190038600
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: October 23, 2018
    Publication date: February 7, 2019
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • Medicaments for the treatment or prevention of fibrotic diseases
    Patent number: 10154990
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: December 18, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20160136133
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: December 29, 2015
    Publication date: May 19, 2016
    Inventors: John Edward Park, Gerald Juergen Roth, Armin Heckel, Nveed Chaudhary, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20150210778
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: April 13, 2015
    Publication date: July 30, 2015
    Inventors: Joanne VAN RYN, John Edward PARK, Norbert HAUEL, Ulrich KUNZ, Tobias LITZENBURGER, Keith CANADA, Sanjaya SINGH, Alisa K. WATERMAN
  • Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
    Patent number: 9034822
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 19, 2015
    Assignee: Boehringer Igelheim International GmbH
    Inventors: Joanne Van Ryn, John Edward Park, Norbert Hauel, Ulrich Kunz, Tobias Litzenburger, Keith Canada, Sanjaya Singh, Alisa Waterman
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20140296217
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 2, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: John Edward PARK, Gerald Juergen ROTH, Armin HECKEL, Nveed CHAUDHARY, Trixi BRANDL, Georg DAHMANN, Matthias GRAUERT
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20140128409
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: January 13, 2014
    Publication date: May 8, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John Edward PARK, Nveed CHAUDHARY, Gerald Juergen ROTH, Armin HECKEL, Thorsten LEHMANN-LINTZ, Joerg KLEY
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20130289248
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: June 13, 2013
    Publication date: October 31, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne VAN RYN, John Edward PARK, Norbert HAUEL, Ulrich KUNZ, Tobias LITZENBURGER, Keith CANADA, Sanjaya SINGH, Alisa WATERMAN
  • Anticoagulant antidotes comprising antibodies that bind dabigatran and/or related compounds
    Patent number: 8486398
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: July 16, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Joanne Van Ryn, John Edward Park, Norbert Hauel, Ulrich Kunz, Tobias Litzenburger, Keith Canada, Sanjaya Singh, Alisa Waterman
  • ANTICOAGULANT ANTIDOTES
    Publication number: 20120027780
    Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.
    Type: Application
    Filed: January 20, 2011
    Publication date: February 2, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Joanne Van Ryn, John Edward Park, Norbert Hauel, Ulrich Kunz, Tobias Litzenburger, Keith Canada, Sanjaya Singh, Alisa Waterman
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20120004202
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: March 31, 2011
    Publication date: January 5, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John Edward PARK, Nveed CHAUDHARY, Gerald Juergen ROTH, Armin HECKEL, Thorsten LEHMANN-LINTZ, Joerg KLEY
  • COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE PROCESSES
    Publication number: 20110076238
    Abstract: The invention relates to the use of anticholinergics for preparing a pharmaceutical composition for the prevention and treatment of proliferative processes.
    Type: Application
    Filed: December 8, 2010
    Publication date: March 31, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John Edward PARK, Nveed CHAUDHARY, Michael P. PIEPER
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20100204211
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: December 22, 2009
    Publication date: August 12, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: John Edward PARK, Gerald Juergen ROTH, Armin HECKEL, Nveed CHAUDHARY, Trixi BRANDL, Georg DAHMANN, Matthias GRAUERT
  • MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
    Publication number: 20090048267
    Abstract: The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1, to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.
    Type: Application
    Filed: May 12, 2008
    Publication date: February 19, 2009
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: John Edward PARK, Nveed Chaudhary, Thorsten Lehmann-Lintz, Armin Heckel, Gerald Juergen Roth, Joerg Kley, Trixi Brandl, Georg Dahmann, Matthias Grauert
  • FAP-activated anti-tumor prodrugs
    Publication number: 20040033957
    Abstract: The present invention relates to prodrugs which are capable of being converted into prodrug intermediates of a cytotoxic or cytostatic drug, by the catalytic action of FAP&agr;, said prodrugs exhibit
    Type: Application
    Filed: May 6, 2003
    Publication date: February 19, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Erik Patzelt, John Edward Park, Stefan Peters